R. Conley

Publications205
h-index51
Citations10,084
Highly Influential Citations371
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • J. Kane
  • 1,799 Publications, 51,173 Citations
  • J. Lieberman
  • 824 Publications, 76,296 Citations
  • H. Meltzer
  • 1,248 Publications, 66,889 Citations
  • R. Roberts
  • 149 Publications, 7,489 Citations
  • Publications
  • Influence
Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects.
BACKGROUND Suicide is a major public health concern. Although authors of many studies have examined the neurobiological aspects of suicide, the molecular mechanisms associated with suicidal behavior… Expand
  • 689
  • 21
  • PDF
Decisional capacity for informed consent in schizophrenia research.
BACKGROUND The adequacy of subjects' informed consent to research is the focus of an important public and professional debate. The potential impairment of decisional capacity in persons with… Expand
  • 455
  • 20
  • PDF
Management of treatment resistance in schizophrenia
A systematic approach to the evaluation and characterization of treatment resistance in schizophrenia has become increasingly important since the introduction of the second-generation antipsychotics.… Expand
  • 281
  • 20
A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.
OBJECTIVE The safety and efficacy of risperidone and olanzapine were compared in a double-blind trial that used doses widely accepted in clinical practice. METHOD Subjects (N=377) who met DSM-IV… Expand
  • 332
  • 15
Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial
Importance Migraine is a disabling neurological disease characterized by severe headache attacks. Treatment options reduce migraine frequency for many patients, but adverse effects lead to… Expand
  • 176
  • 14
  • PDF
The cost of relapse and the predictors of relapse in the treatment of schizophrenia
BackgroundTo assess the direct cost of relapse and the predictors of relapse during the treatment of patients with schizophrenia in the United States.MethodsData were drawn from a prospective,… Expand
  • 214
  • 11
  • PDF
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update.
BACKGROUND A panel of academic psychiatrists and pharmacists, clinicians from the Texas public mental health system, advocates, and consumers met in June 2006 in Dallas, Tex., to review recent… Expand
  • 266
  • 10
Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.
OBJECTIVE Hyperprolactinemia and associated side effects often occur with antipsychotics. The authors investigated the effect of adjunctive treatment with aripiprazole on hyperprolactinemia and… Expand
  • 188
  • 10
Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia.
OBJECTIVE Multiple quantifiable biologic abnormalities have been localized to the hippocampus in schizophrenia. Alterations in glutamate-mediated transmission at N-methyl-D-aspartic acid… Expand
  • 365
  • 9
  • PDF
Evaluation of treatment-resistant schizophrenia.
A systematic approach to the evaluation and characterization of treatment resistance in schizophrenia has become increasingly important since the introduction of clozapine, risperidone, and… Expand
  • 223
  • 8
  • PDF